Inflammatory breast cancer: Clinical progress and the main problems that must be addressed

[1]  S. Steinberg,et al.  Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Merajver,et al.  Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. , 2002, Molecular cancer therapeutics.

[4]  M. Rahbar,et al.  Case Control Study of Prognostic Markers and Disease Outcome in Inflammatory Carcinoma Breast: A Unique Clinical Experience , 2001, The breast journal.

[5]  S. Barsky,et al.  An Intact Overexpressed E-cadherin/α,β-Catenin Axis Characterizes the Lymphovascular Emboli of Inflammatory Breast Carcinoma , 2001 .

[6]  S. Merajver,et al.  Persistent E-Cadherin Expression in Inflammatory Breast Cancer , 2001, Modern Pathology.

[7]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[8]  S. Ebbs,et al.  Multimodality therapy in inflammatory breast cancer: is there a place for surgery? , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Merajver,et al.  Molecular biology of breast cancer metastasis: Inflammatory breast cancer: clinical syndrome and molecular determinants , 2000, Breast Cancer Research.

[10]  S. Barsky,et al.  A novel human xenograft model of inflammatory breast cancer. , 1999, Cancer research.

[11]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  T. Odom-Maryon,et al.  Beyond Palliative Mastectomy in Inflammatory Breast Cancer—A Reassessment of Margin Status , 1999, Annals of Surgical Oncology.

[13]  J. Ahomadégbé,et al.  Association of c‐erbB2‐gene amplification with poor prognosis in non‐inflammatory breast carcinomas but not in carcinomas of the inflammatory type , 1994, International journal of cancer.

[14]  A. Levine,et al.  Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. , 1993, Journal of the National Cancer Institute.

[15]  J. Julien,et al.  The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. , 1993, British Journal of Cancer.

[16]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Hortobagyi,et al.  Inflammatory breast cancer: a review. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Tommasi,et al.  Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease , 1989, Cancer.

[19]  C. Perez,et al.  Inflammatory carcinoma of the breast: treatment results on 107 patients. , 1989, International journal of radiation oncology, biology, physics.

[20]  B. Asselain,et al.  Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis , 1987, Cancer.

[21]  S. Friedman,et al.  Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Levine,et al.  Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. , 1985, Journal of the National Cancer Institute.

[23]  J. Siegel.  Inflammatory carcinoma of the breast. , 1952, A.M.A. archives of dermatology and syphilology.

[24]  T. Iwanaga,et al.  Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. , 2001, Cancer research.

[25]  S. Barsky,et al.  An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. , 2001, Cancer research.

[26]  A. Buzdar,et al.  Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. , 2000, AJR. American journal of roentgenology.

[27]  G. Hortobagyi,et al.  Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center , 1997, Cancer Chemotherapy and Pharmacology.

[28]  B. Asselain,et al.  Prognostic factors in inflammatory breast cancer and therapeutic implications. , 1994, European journal of cancer.

[29]  P. Levine,et al.  Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. , 1993, Cancer investigation.

[30]  L. Hayman,et al.  Correspondence , 1992, Neuroradiology.

[31]  Á. Balogh,et al.  Primary inflammatory carcinoma of the breast. , 1983, Acta chirurgica Hungarica.